| POLISH FINANCIAL SUPERVISION AUTHORITY | |||||||||||
| UNI - EN REPORT No | 95 | / | 2014 | ||||||||
| Date of issue: | 2014-09-11 | ||||||||||
| Short name of the issuer | |||||||||||
| SOPHARMA AD | |||||||||||
| Subject | |||||||||||
| Current report 95 buy back 11092014 | |||||||||||
| Official market - legal basis | |||||||||||
| Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne | |||||||||||
| Unofficial market - legal basis | |||||||||||
| Contents of the report: | |||||||||||
| SOPHARMA AD (the “Company") hereby informs that from 4 September2014 up to and including 10 September 2014 the Company bought 3800 own shares representing 0.0029% of the share capital of the Company, to the total value of 15 868.8 BGN on the Bulgarian Stock Exchange, the average price per share was 4.18 BGN. The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010. The total number of treasury shares after these transactions is 5 075 855, representing 3.85% of the share capital of the Company. | |||||||||||
| Annexes | |||||||||||
| File | Description | ||||||||||
| Current report 95 buy back 11092014.doc | Current report 95 buy back 11092014 | ||||||||||
| SOPHARMA AD | |||||||||||||
| (fullname of the issuer) | |||||||||||||
| SOPHARMA AD | Farmaceutyczny (far) | ||||||||||||
| (short name of the issuer) | (sector according to clasification of the WSE in Warsow) | ||||||||||||
| 1220 | Sofia | ||||||||||||
| (post code) | (city) | ||||||||||||
| IlienskoShosse | 16 | ||||||||||||
| (street) | (number) | ||||||||||||
| +359 2 813 42 00 | +359 2 936 02 86 | ||||||||||||
| (phone number) | (fax) | ||||||||||||
| (e-mail) | (web site) | ||||||||||||
| nd | |||||||||||||
| (NIP) | (REGON) | ||||||||||||
| SIGNATURE OF PERSONS REPRESENTING THE COMPANY | |||||
| Date | Name | Position / Function | Signature | ||
| 2014-09-11 | Ognian Donev | Executive director | |||
